The Egyptian Drug Authority (EDA) said in a statement on Thursday that it has activated a package of incentive measures for contract manufacturing pharmaceuticals and medical supplies so as to open new markets and increase the export value of Egyptian pharmaceutical products and increase incentives for pharmaceutical investment. Contract manufacturing allows manufacturing with the aim of export only. EDA spokesman Aly El-Ghamrawy said that contract manufacturing has been applied to pharmaceutical products and medical supplies which are unregistered with the EDA that are produced locally for export. El-Ghamrawy said that four pharmaceutical companies have applied for contract manufacturing in 2019 and 2020, and 57 products have been approved for export to Sudan, Saudi Arabia, the UK, Canada, Cyprus and Yemen. In addition, three pharmaceuticals were exported according to this system in 2019 to Sudan, and two others during 2020 to Syria and the UK. Forty-four import approvals were issued to release production materials for export for five medical supply factories during 2019, and 11 import approvals were issued to release production materials for export in favour of three medical supply factories in 2020.
